Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.

34 In the LevoRep study, assignment to levosimendan was associated with a 50% lower risk of death, heart transplant, or acute HF compared with placebo, but this difference did not quite reach statistical significance (HR 0.50, 95% CI 0.24–1.025; P = 0.069). 21 It is important to highlight that in our study, repetitive levosimendan administration was safe and well tolerated: the adverse events rate was comparable between the levosimendan and placebo groups, including a similar incidence of patients with an adverse event leading to discontinuation of the therapy.

also in 679 other papers